Redpin Therapeutics

Redpin Therapeutics, Inc., a pioneering chemogenetics company developing uniquely controllable gene therapies to address intractable diseases of the nervous system, today announced the appointment of Abhinav A. Shukla, PhD, as its Chief Technical Operations Officer (CTOO). Redpin recently announced the...

4BIO Capital and Arkin Bio Ventures lead first close joined by Takeda Ventures and existing investors Redpin Therapeutics, Inc., a pioneering chemogenetics company developing uniquely controllable gene therapies to address intractable diseases of the nervous system, today announced it has...

Engineered receptors and ultrapotent, FDA-approved agonists enable clinical applications of chemogenetics Novel ion channel-based platform allows targeted cell activation or silencing controlled by low doses of the anti-smoking drug varenicline Redpin leveraging platform to advance pipeline of targeted cell therapies...

Company advancing novel platform technologies to enable non-invasive, targeted regulation of neuronal cell activity Aiming to address currently intractable neurologic and psychiatric diseases Redpin Therapeutics today announced the appointment of David Bleakman, PhD, as its Chief Scientific Officer (CSO). Founded...